Abstract:Poly (ADP-ribose) polymerase (PARP) inhibitors (PARPi) have exhibited great promise in the treatment of tumors with homologous recombination (HR) deficiency, however, PARPi resistance, which ultimately recovers DNA repair and cell progress, has become an enormous clinical challenge. Recently, KP372-1 was identified as a novel potential anticancer agent that targeted the redox enzyme, NAD(P)H:quinone oxidoreductase 1 (NQO1), to induce extensive reactive oxygen species (ROS) generation that amplified DNA damage, leading to cancer cell death. To overcome PARPi resistance and expand its therapeutic utility, we investigated whether a combination therapy of a sublethal dose of KP372-1 with a nontoxic dose of PARPi rucaparib would synergize and enhance lethality in NQO1 over-expressing cancers. We reported that the combination treatment of KP372-1 and rucaparib induced a transient and dramatic AKT hyperactivation that inhibited DNA repair by regulating FOXO3a/GADD45α pathway, which enhanced PARPi lethality and overcame PARPi resistance. We further found that PARP inhibition blocked KP372-1-induced PARP1 hyperactivation to reverse NAD + /ATP loss that promoted Ca 2+ -dependent autophagy and apoptosis. Moreover, pretreatment of cells with BAPTA-AM, a cytosolic Ca 2+ chelator, dramatically rescued KP372-1- or combination treatment-induced lethality and significantly suppressed PAR formation and γH2AX activation. Finally, we demonstrated that this combination therapy enhanced accumulation of both agents in mouse tumor tissues and synergistically suppressed tumor growth in orthotopic pancreatic and non-small-cell lung cancer xenograft models. Together, our study provides novel preclinical evidence for new combination therapy in NQO1 + solid tumors that may broaden the clinical utility of PARPi.

Induction of Apoptosis in MDA-MB-231 Breast Cancer Cells by a PARP1-targeting PROTAC Small Molecule

Identification of Probe-Quality Degraders for Poly(ADP-ribose) Polymerase-1 (PARP-1)

PARP1: A Promising Target for the Development of PARP1-based Candidates for Anticancer Intervention

A PARP1 PROTAC as a novel strategy against PARP inhibitor resistance via promotion of ferroptosis in p53-positive breast cancer

Discovery of a potent and selective PARP1 degrader promoting cell cycle arrest via intercepting CDC25C-CDK1 axis for treating triple-negative breast cancer

Synthesis and biological evaluation of a tumor-selective degrader of PARP1

Selective degradation of PARP2 by PROTACs via recruiting DCAF16 for triple-negative breast cancer

Engineering POLYTAC Nanoparticles for Bioorthogonal Click Reaction-Enforced Protein Degradation and Breast Cancer Therapy

Discovery of a potent PARP1 PROTAC as a chemosensitizer for the treatment of colorectal cancer

KP372-1-Induced AKT Hyperactivation Blocks DNA Repair to Synergize With PARP Inhibitor Rucaparib via Inhibiting FOXO3a/GADD45α Pathway

In Vitro and in Vivo Degradation of Programmed Cell Death Ligand 1 (PD-L1) by a Proteolysis Targeting Chimera (PROTAC).

Discovery of novel anti-tumor compounds targeting PARP-1 with induction of autophagy through in silico and in vitro screening

Crystal Structure-Based Discovery of a Novel Synthesized PARP1 Inhibitor (OL-1) with Apoptosis-Inducing Mechanisms in Triple-Negative Breast Cancer

Uncoupling of PARP1 trapping and inhibition using selective PARP1 degradation

Discovery, Mechanism and Metabolism Studies of 2,3-Difluorophenyl-linker-containing PARP1 Inhibitors with Enhanced in Vivo Efficacy for Cancer Therapy

Discovery of Novel Proteolysis-Targeting Chimera Molecules as Degraders of Programmed Cell Death-Ligand 1 for Breast Cancer Therapy

Designing an eEF2K-Targeting PROTAC small molecule that induces apoptosis in MDA-MB-231 cells

The discovery of a potent PARP1 inhibitor Senaparib

Discovery of 4-Hydroxyquinazoline Derivatives as Small Molecular BET/PARP1 Inhibitors That Induce Defective Homologous Recombination and Lead to Synthetic Lethality for Triple-Negative Breast Cancer Therapy

PARP1 inhibitors induce pyroptosis via caspase 3-mediated gasdermin E cleavage

Nuclear PARP1‐Targeted Photosensitizer as a Dual‐Mode DNA‐Damaging Agent and Immune Activator for Tumor Ablation (Adv. Healthcare Mater. 31/2023)